Femasys Jumps Almost 30% as Nasdaq Deadline Remains
Femasys Inc. shares rallied about 30% on Friday, a late-session pop for the women’s health stock as U.S. small caps pushed higher heading into Memorial Day weekend.
Femasys Shares Surge 15% Following UNC Health Adoption of FemaSeed Across OB/GYN Clinics
Femasys stock climbed 15.05% on Friday following an agreement with UNC Health to roll out the FemaSeed fertility portfolio in its OB/GYN clinics.
FEMY investor dashboard FemaSeed rollout
UNC Health access meets a very small revenue base
Market data: August 28, 2026, 13:52 EDT · Partnership announced August 26, 2026
Share price
$3.21
+15.05% from $2.79 prior close
Value added
≈$1.41M
About 4.25× quarterly sales
Trading activity
402.7K
Day range: $2.81–$3.33
Market value
$10.78M
Micro-cap valuation at 13:52 EDT
FemaSeed clinical comparison
Commercial path
FemVueUltrasound-based fertility evaluation
SpermVueMale fertility screening
FemaSeed CompleteIn-office intratubal insemination
UNC Health OB/GYN networkStatewide access; site count and pricing undisclosed
Financial scale
| Measure | Latest |
|---|---|
| Q2 sales | $331,827 |
| Year-over-year change | −18.9% |
| Q2 net loss | $4.47M |
| Loss / sales | 13.5× |
| June 30 cash | $1.4M |
| Subsequent placement | $30M |
| Potential total with warrants | Up to $90M |
Signals and risks
- Distribution signal: An academic health system adds credibility to the OB/GYN commercialization model.
- Clinical signal: The reported 16% per-cycle rate exceeded the 6.7% historical IUI comparator.
- Conversion gap: No minimum orders, pricing, rollout timetable or revenue commitment was disclosed.
- Cash runway: The placement materially improves liquidity, but operating losses remain large beside sales.
- Next proof point: Investors need procedure volume, repeat ordering and visible quarterly revenue growth.
Sources: Femasys partnership release dated August 26, 2026; Femasys Q2 2026 results; FemaSeed pivotal-trial release; U.S. market data at 13:52 EDT. Equity-value increase is calculated from current market capitalization and the 15.05% share move. Trial figures are company-reported and use a historical IUI comparator.
Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?
Femasys Inc. is a Georgia-based medical device and biotherapeutics company specializing in women’s reproductive health solutions. Founded and led by CEO Kathy Lee-Sepsick, Femasys aims to “transform women’s healthcare” by addressing long-neglected needs with non-surgical, in-office technologiesfemasys.comgurufocus.com. The company’s mission is to provide women with minimally invasive, office-based alternatives that improve patient care and reduce costs, in areas ranging from infertility to contraception and cancer diagnosticsfemasys.comgurufocus.com. Safety and accessibility are emphasized – Femasys notes that advances in female reproductive health are “long overdue,” and its products are designed to be used without general anesthesia or hospital infrastructureglobenewswire.cominvesting.com.
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?
Femasys stock has been on a rollercoaster ride in recent sessions. As of October 17, 2025, FEMY traded around the mid-$0.70s per share – more than double its price just a few weeks prior, and well off its 52-week low near $0.31 ts2.tech. On October 16, the stock spiked dramatically: opening near $0.55, it rallied to an intraday high of $0.84 before settling at $0.745 by the close finance.yahoo.com. This explosive move came amid unusually heavy volume stockinvest.us, indicating heightened investor interest.
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones
Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine inseminationglobenewswire.comstocktitan.net. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgeryir.femasys.comir.femasys.com.
TechStock² Updates
